News about "Zydus Lifesciences"

Zydus Lifesciences to Launch Protection Against New Strain of Influenza Virus

The Quadrivalent Inactivated Influenza vaccine has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad which has proven capabilities in researching, developing, and manufacturing of safe and efficacious vaccines.

Zydus Lifesciences | 28/02/2025 | By Aishwarya

Zydus and Synthon to Commercialise Novel 505(B)(2) Oncology Product in US

Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product.

Zydus Lifesciences | 13/02/2025 | By Aishwarya

Zydus Reports Robust Growth in Q3 FY25 with a 17 Percent Increase in Revenue

Zydus Lifesciences recorded revenue from operations at INR 52,691 million, marking a 17 percent increase year-over-year.

Zydus Lifesciences | 06/02/2025 | By Aishwarya

Zydus's Chairman Pankaj R Patel Conferred with Padma Bhushan

With a Masters in Pharmaceutics and Pharmaceutical Technology from the L.M. College of Pharmacy and an alumni of the Indian Institute of Management (IIM), Ahmedabad, he was always driven by a passion to become a pharma entrepreneur.

Zydus Lifesciences | 27/01/2025 | By Aishwarya |  111

Zydus Signs Licensing and Supply Agreement with Viwit Pharmaceuticals

As per the terms of the agreement, Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVISTTM and DOTAREM, following the receipt of requisite regulatory approval.

Zydus Lifesciences | 16/09/2024 | By Aishwarya |  139

Zydus Gets Final Approval from USFDA for Scopolamine Transdermal System

Scopolamine Transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery.

Zydus Lifesciences | 31/08/2024 | By Aishwarya |  135

Zydus Gets Approval from COFEPRIS to Market Mamitra

Zydus Lifesciences has announced that COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) has granted marketing approval for Mamitra, a Trastuzumab biosimilar.

Zydus Lifesciences | 31/07/2024 | By Aishwarya |  116

Zydus Gets Tentative Approval from USFDA for Azilsartan Medoxomil Tablets

Zydus Lifesciences Ltd. has secured a tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, 40 mg and 80 mg (USRLD: Edarbi tablets).

Zydus Lifesciences | 06/07/2024 | By Aishwarya |  219

Zydus and Dr. Reddy to Co-Market Pertuzumab Biosimilar in India

Zydus Lifesciences and Dr. Reddy’s Laboratories Ltd. have announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India.

Zydus Lifesciences | 05/07/2024 | By Aishwarya |  639

Zydus Completes Enrolment for EPICS IIITM Phase 2b/3 Trial of Saroglitazar Mg

Zydus Lifesciences has completed enrolment of Phase 2b/3 EPICS IIITM trial of Saroglitazar Mg in patients with Primary Biliary Cholangitis (PBC).

Zydus Lifesciences | 10/05/2024 | By Aishwarya |  234